 |
Parkinsons News: 273 headlines |
|
|||||
Celebrity Fight Night Video  |
||||||||
|
||||||||
|
||||||||
| Sources used by our Parkinsons News Channel Research Team: | ||||||||
| The New York Times, CNN, FOX, CBS, BBC, Mayo Clinic, Johns Hopkins Medicine, UCLA Medical Center, National Institute of Health, Stanford Hospital, Memorial Sloan- Kettering, Yale Cancer Center, Massachusetts General Hospital, Brigham and Women's Hospital, University of Michigan, M. D. Anderson Cancer Center, National Institute of Health, American Cancer Association, NBC, Reuters News, American College of Cardiology, Journal of the American Medical Association & 100's more | ||||||||
| Links | ||||||||
| Barrow Neurological Institute | ||||||||
| Archives |
Friday
Science & Technology at Scientific American.com: Parkinson's drug may raise risk of valve trouble
Parkinson's drug may raise risk of valve trouble (click for more):
"In some cases, patients taking a Parkinson's drug called cabergoline may experience damage to heart valves, a study suggests. High cumulative doses of and long-term treatment with this drug are risk factors for the development of 'valvulopathy,' Japanese doctors report in the journal Neurology this month.
Cabergoline is a so-called dopamine agonist used to control movement problems caused by Parkinson's disease. Other dopamine agonists include pergolide and pramipexole.
Dr. Mitsutoshi Yamamoto and colleagues determined the frequency of valvulopathy in 210 consecutive Parkinson's patients admitted to Kagawa Prefectural Central Hospital in Takamatsu.
Among the 125 dopamine agonist-treated patients, 16 received cabergoline, 66 received pergolide, 16 pramipexole, and 27 were past users of a dopamine agonist. The remaining 85 patients were not treated with any dopamine agonist and served as the control group.
ADVERTISEMENT (article continues below)
60-Second Science Podcast from Scientific American
According to the investigators, the frequency of valvulopathy was significantly higher in the cabergoline-treated patients relative to control patients (68.8 percent vs. 17.6 percent). The frequency was similar between pergolide-treated and pramipexole-treated patients (28.8 percent and 25 percent, respectively..."
"In some cases, patients taking a Parkinson's drug called cabergoline may experience damage to heart valves, a study suggests. High cumulative doses of and long-term treatment with this drug are risk factors for the development of 'valvulopathy,' Japanese doctors report in the journal Neurology this month.
Cabergoline is a so-called dopamine agonist used to control movement problems caused by Parkinson's disease. Other dopamine agonists include pergolide and pramipexole.
Dr. Mitsutoshi Yamamoto and colleagues determined the frequency of valvulopathy in 210 consecutive Parkinson's patients admitted to Kagawa Prefectural Central Hospital in Takamatsu.
Among the 125 dopamine agonist-treated patients, 16 received cabergoline, 66 received pergolide, 16 pramipexole, and 27 were past users of a dopamine agonist. The remaining 85 patients were not treated with any dopamine agonist and served as the control group.
ADVERTISEMENT (article continues below)
60-Second Science Podcast from Scientific American
According to the investigators, the frequency of valvulopathy was significantly higher in the cabergoline-treated patients relative to control patients (68.8 percent vs. 17.6 percent). The frequency was similar between pergolide-treated and pramipexole-treated patients (28.8 percent and 25 percent, respectively..."